{"url_path":"/sec/ewtx/8-k/2026-07-16/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 (b) of Form 8-K is attached hereto as Exhibit 99.1 and is incorporated herein by reference.","topic":"sec","document":{"doc_type":"8-K/A","doc_date":"2026-07-16","source_url":"https://www.sec.gov/Archives/edgar/data/1710072/0001104659-26-084088-index.html","accession_number":"0001104659-26-084088","cik":"0001710072","ticker":"EWTX","issuer_name":"Edgewise Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1710072/0001104659-26-084088-index.html","primary_entity_key":"0001710072","primary_entity_name":"Edgewise Therapeutics, Inc."},"word_count":88,"has_tables":true,"body_markdown":"Item 9.01(b) of Form 8-K is attached hereto as Exhibit 99.1 and is incorporated herein by reference.\n\n \n\n(d) Exhibits:\n\n \n\n**Exhibit No.**\n \n**Description**\n\n[99.1](tm2620181d2_ex99-1.htm)\n \n[Unaudited pro forma condensed financial information](tm2620181d2_ex99-1.htm)\n\n \n \n \n\n104\n \nCover Page Interactive Data File (embedded within the Inline XBRL documents)\n\n \n\n \n\n \n\n**SIGNATURES**\n\n** **\n\nPursuant to the requirements of the Securities\nExchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n**EDGEWISE THERAPEUTICS,\nINC.**\n \n\n \n \n \n\nBy:\n/s/\nMichael Nofi\n \n\n \nMichael\nNofi\n \n\n \nChief\nFinancial Officer\n \n\n \n\nDate: July 16, 2026"}